Drugs / AlloEx
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05152394 | Aug 2024 → Jan 2027 expected | Parkinson disease | The Foundation for Orthopaedics and Regenerative Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05152368 | Sep 2022 → Jan 2026 overdue | trigeminal neuralgia | The Foundation for Orthopaedics and Regenerative Medicine | Recruiting | No outcome recorded |
| Phase 1 | NCT05158101 | Feb 2022 → Feb 2026 overdue | stroke disorder | The Foundation for Orthopaedics and Regenerative Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AlloEx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05152368 ↗ |
| Modality | Other / unclassified | “cultured allogeneic adult umbilical cord derived mesenchymal stem cell exosomes” NCT05152368 ↗ |
| Route | Intranasal | “Patients will receive an intranasal instillation of UC-MSCs exosomes.” NCT05152368 ↗ |